Sounds like our Beacon analyst, David Kideckel, was either at or listened to the proceedings of the AGM.  Reiterating his comments and belief that this company is going to burst out in 2018.

"Based on the potential upcoming milestones, Kideckel concluded, "We believe 2018 holds great promise for Resverlogix." He reiterated Beacon's Buy rating and CA$8.55 per share price target price on the biotech, whose stock is currently trading at around CA$2 per share".

I tend to agree with his assessment.  There is a lot that this little biotech is at the forefront of.  We just need DM to spread the word and get some serious interest.  When you're this far in the lead, you have to believe that there are others following you.  It seems Kideckel does.

https://www.streetwisereports.com/article/2017/12/20/biotech-receives-major-endorsement-from-world-leading-pharma-company.html

DYODD

masila